Abstract:AURKA is predominantly famous as an essential mitotic kinase. Recent findings have also established its critical role in a plethora of other biological processes including ciliogenesis, mitochondrial dynamics, neuronal outgrowth, DNA replication and cell cycle progression. AURKA overexpression in numerous cancers is strongly associated with poor prognosis and survival. Still no AURKA-targeted drug has been approved yet, partially because of the associated collateral toxicity and partly due to its limited efficacy as a single agent in a wide range of tumors. Mechanistically, AURKA overexpression allows it to phosphorylate numerous pathological substrates promoting highly aggressive oncogenic phenotypes. Our review examines the most recent advances in AURKA regulation and focuses on 33 such direct cancer-specific targets of AURKA and their associated oncogenic signaling cascades. One of the common themes that emerge is that AURKA is often involved in a feedback loop with its substrates, which could be the decisive factor causing its sustained upregulation and hyperactivation in cancer cells, an Achilles heel not exploited before. This dynamic interplay between AURKA and its substrates offers potential opportunities for targeted therapeutic interventions. By targeting these substrates, it may be possible to disrupt this feedback loop to effectively reverse AURKA levels, thereby providing a promising avenue for developing safer AURKA-targeted therapeutics. Additionally, exploring the synergistic effects of AURKA inhibition with its other oncogenic and/or tumor-suppressor targets could provide further opportunities for developing effective combination therapies against AURKA-driven cancers, thereby maximizing its potential as a critical drug target.

Aurora Kinase Inhibitors: a Patent Review (2014-2020)

Aurora Kinases As Targets for Cancer Therapy.

Aurora‐A Kinase: A Potent Oncogene and Target for Cancer Therapy

Revisiting Aurora Kinase B: A Promising Therapeutic Target for Cancer Therapy.

New Advances in Aurora Kinase and Its Anti-tumor Inhibitors

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics

The Progress of Aurora Kinase Inhibitors

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

The Progress of Aurora Kinase and its inhibitors

Research Development of Aurora-A Kinase

Progress in the Development of Aurora Kinase Inhibitors

Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

An updated patent review of AKT inhibitors (2020 - present)

Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present)

Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 - 2019)

Selective Aurora Kinase Inhibitors Identified Using a Taxol-Induced Checkpoint Sensitivity Screen

Recent researches for dual Aurora target inhibitors in antitumor field

The significant others of aurora kinase a in cancer: combination is the key

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.